- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07939750
Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
Comparison of the Effect of Metformin-Sotagliflozin Versus Metformin-Empagliflozin Combination Therapy on Glycemic Control Measured by HbA1c in Patients With Type 2 Diabetes Mellitus
The goal of this randomized controlled trial is to compare two medicines added to metformin for blood sugar control in adults with type 2 diabetes whose HbA1c remains between 7.0% and 10.0% despite a stable dose of metformin. The main question it aims to answer is: Does adding sotagliflozin (a dual SGLT1/SGLT2 inhibitor) lower HbA1c more than adding empagliflozin (a selective SGLT2 inhibitor) after 24 weeks? Participants will continue their usual metformin dose and will be randomly assigned to take either sotagliflozin 200 mg or empagliflozin 10 mg once daily for 24 weeks. They will be reviewed at 4, 12 and 24 weeks for adherence, side effects and adverse events, and HbA1c will be measured at baseline and at 24 weeks.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Pakistan has one of the highest adult diabetes prevalences in the world, and many patients fail to reach HbA1c targets on metformin monotherapy and require a second agent. SGLT2 inhibitors such as empagliflozin are established second-line agents. Sotagliflozin additionally inhibits intestinal SGLT1, blunting post-prandial glucose absorption and enhancing incretin release, which may provide additional glucose lowering. No head-to-head randomized comparison of these two combinations has been performed in Pakistan.
This is a single-centre, open-label, parallel-group randomized controlled trial with blinded outcome assessment, conducted at the Department of Medicine and Diabetic Clinic/Medicine OPD, Allied Hospital-I, Faisalabad Medical University. 140 patients (70 per group) will be enrolled by consecutive sampling and randomized 1:1. Sample size was calculated for 95% confidence, 80% power, SD of HbA1c change 1%, and a minimal clinically important difference of 0.5%, inflated by 10% for loss to follow-up. HbA1c will be measured by a standardized laboratory method at baseline and 24 weeks, with laboratory staff blinded to group allocation. Data will be analysed in SPSS; mean change in HbA1c will be compared using the independent-samples t-test (p ≤ 0.05 significant), with stratification for age, gender, BMI, duration of diabetes and baseline HbA1c.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Sheraz Ali
- Número de teléfono: +923330360744
- Correo electrónico: sheraz.mirza10@gmail.com
Ubicaciones de estudio
-
-
Punjab Province
-
Faisalabad, Punjab Province, Pakistán, 38000
- Allied Hospital, Faisalabad Medical University
-
Contacto:
- Sheraz Ali
- Número de teléfono: 03330360744
- Correo electrónico: sheraz.mirza10@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 30 to 65 years, male or female
- Diagnosed type 2 diabetes mellitus (ADA criteria)
- Inadequately controlled on metformin: stable dose ≥1500 mg/day (or maximum tolerated dose) for at least 8 weeks, with HbA1c ≥7.0% and ≤10.0% at screening
- Willing to provide written informed consent and attend scheduled follow-up
Exclusion Criteria:
- Type 1 diabetes mellitus or secondary diabetes
- Use of any SGLT inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor or sulfonylurea within the previous 8 weeks
- eGFR <45 mL/min/1.73 m², or significant hepatic impairment
- Pregnancy, lactation, or women of childbearing potential not using contraception
- Haemoglobinopathies
- Known hypersensitivity to any study drug, or any condition making the patient unsuitable for the trial
- Recurrent genital/urinary tract infections or history of Fournier's gangrene
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Metformin + Sotagliflozin (Group A)
Existing stable dose of metformin plus sotagliflozin 200 mg orally once daily for 24 weeks. |
200 mg tablet orally once daily for 24 weeks continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated) |
|
Comparador activo: Metformin + Empagliflozin (Group B)
Existing stable dose of metformin plus empagliflozin 10 mg orally once daily for 24 weeks. |
continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated) 10 mg tablet orally once daily for 24 weeks |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in HbA1c From Baseline to Week 24
Periodo de tiempo: Baseline and 24 weeks
|
Glycated haemoglobin (%) measured by a standardized laboratory method. Change calculated as baseline HbA1c minus week-24 HbA1c for each participant; a between-group difference ≥0.5% is considered clinically meaningful. |
Baseline and 24 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Adverse Events
Periodo de tiempo: Up to 24 weeks (assessed at weeks 4, 12 and 24)
|
Adverse events including genital/urinary tract infections, hypoglycaemia and gastrointestinal symptoms, recorded at follow-up visits. |
Up to 24 weeks (assessed at weeks 4, 12 and 24)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sheraz Ali, Faisalabad Medical University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades metabólicas
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Enfermedades Nutricionales y Metabólicas
- Diabetes Mellitus, Tipo 2
- Químicos orgánicos
- Biguanides
- Guanidinas
- Amidinos
- Metformina
- (2S,3R,4R,5S,6R)-2-(4-cloro-3-(4-etoxibencil)fenil)-6-(metiltio)tetrahidro-2H-piran-3,4,5-triol
- empagliflozin
Otros números de identificación del estudio
- 48.ERC/FMU/2025-26/434
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data will not be shared; aggregate results will be published in a peer-reviewed journal.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .